Table of Contents List of Tables List of Figures Introduction Global Markets Direct Report Coverage Down Syndrome - Overview Down Syndrome - Therapeutics Development Pipeline Overview Pipeline by Companies Pipeline by Universities/Institutes Products under Development by Companies Products under Development by Universities/Institutes Down Syndrome - Therapeutics Assessment Assessment by Target Assessment by Mechanism of Action Assessment by Route of Administration Assessment by Molecule Type Down Syndrome - Companies Involved in Therapeutics Development AC Immune SA Eisai Co Ltd F. Hoffmann-La Roche Ltd ManRos Therapeutics NeuroNascent Inc San Biotechnology Co Ltd Down Syndrome - Drug Profiles ABI-02 - Drug Profile Product Description Mechanism Of Action R&D Progress ACI-24 - Drug Profile Product Description Mechanism Of Action R&D Progress BAN-2401 - Drug Profile Product Description Mechanism Of Action R&D Progress D-217 - Drug Profile Product Description Mechanism Of Action R&D Progress Dosmir - Drug Profile Product Description Mechanism Of Action R&D Progress Gene Therapy to Activate ZSCAN4 for Chromosomal Disorders - Drug Profile Product Description Mechanism Of Action R&D Progress KPO-1143 - Drug Profile Product Description Mechanism Of Action R&D Progress minocycline hydrochloride - Drug Profile Product Description Mechanism Of Action R&D Progress NNI-351 - Drug Profile Product Description Mechanism Of Action R&D Progress pentylenetetrazol - Drug Profile Product Description Mechanism Of Action R&D Progress RO-4938581 - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecule to Inhibit DYRK1A for Alzheimer’s Disease and Down Syndrome - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecule to Inhibit DYRK1A for Down Syndrome - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecules for Down Syndrome - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecules to Inhibit DYRK1A for Alzheimer’s Disease and Down Syndrome - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecules to Inhibit OLIG2 for Down Syndrome - Drug Profile Product Description Mechanism Of Action R&D Progress Down Syndrome - Dormant Projects Down Syndrome - Discontinued Products Down Syndrome - Product Development Milestones Featured News & Press Releases Aug 20, 2018: AC Immune announces important clinical milestones for ACI-24 vaccine in alzheimers disease and down syndrome Sep 12, 2017: AC Immune Completes Recruitment For Low-Dose Cohort In World's First Clinical Trial For Anti-Abeta Vaccine Targeting Alzheimer's Disease-Like Characteristics In Individuals With Down Syndrome Apr 05, 2016: AC Immune Announces Publication of Ground-breaking Scientific Publication on anti-Abeta Vaccine in Preclinical Model of Down Syndrome Feb 05, 2015: Neuronascent Announces Expanded Patent Coverage in Russia for Its Down Syndrome Therapeutics Feb 27, 2013: Roche Research Sheds Light On Improving Neurological Deficits In Mouse Model Of Down Syndrome Appendix Methodology Coverage Secondary Research Primary Research Expert Panel Validation Contact Us Disclaimer

List of Tables Number of Products under Development for Down Syndrome, H1 2019 Number of Products under Development by Companies, H1 2019 Number of Products under Development by Universities/Institutes, H1 2019 Products under Development by Companies, H1 2019 Products under Development by Universities/Institutes, H1 2019 Number of Products by Stage and Target, H1 2019 Number of Products by Stage and Mechanism of Action, H1 2019 Number of Products by Stage and Route of Administration, H1 2019 Number of Products by Stage and Molecule Type, H1 2019 Down Syndrome - Pipeline by AC Immune SA, H1 2019 Down Syndrome - Pipeline by Eisai Co Ltd, H1 2019 Down Syndrome - Pipeline by F. Hoffmann-La Roche Ltd, H1 2019 Down Syndrome - Pipeline by ManRos Therapeutics, H1 2019 Down Syndrome - Pipeline by NeuroNascent Inc, H1 2019 Down Syndrome - Pipeline by San Biotechnology Co Ltd, H1 2019 Down Syndrome - Dormant Projects, H1 2019 Down Syndrome - Discontinued Products, H1 2019List of Figures Number of Products under Development for Down Syndrome, H1 2019 Number of Products under Development by Companies, H1 2019 Number of Products under Development by Universities/Institutes, H1 2019 Number of Products by Targets, H1 2019 Number of Products by Stage and Targets, H1 2019 Number of Products by Mechanism of Actions, H1 2019 Number of Products by Stage and Mechanism of Actions, H1 2019 Number of Products by Routes of Administration, H1 2019 Number of Products by Stage and Routes of Administration, H1 2019 Number of Products by Molecule Types, H1 2019 Number of Products by Stage and Molecule Types, H1 2019

AC Immune SA Eisai Co Ltd F. Hoffmann-La Roche Ltd ManRos Therapeutics NeuroNascent Inc San Biotechnology Co Ltd